RemeGen Co., Ltd. published its Monthly Return for July 2026, confirming that total authorised/registered capital remained unchanged at 564.48 million shares (RMB1 par value). The split between Hong Kong-listed H shares and Shanghai-listed A shares stood at 208.58 million and 355.90 million, respectively.

Issued H shares were unchanged at 208.58 million, and the company affirmed compliance with the Hong Kong Exchange’s minimum 5 percent public-float requirement for PRC issuers. On the A-share register, RemeGen repurchased 13,000 shares on 30 July at RMB109.86 per share for use in employee equity incentive schemes, reducing outstanding A shares to 355.69 million and lifting treasury shares to 207,144. No new shares were issued, nor were any options, warrants or convertibles exercised during the month.

Three ongoing A-share restricted-stock incentive plans still allow up to 2.18 million shares to be granted or transferred from treasury, following prior lapses and attributions. Post-transaction, RemeGen’s total issued share count (excluding treasury shares) stands at 564.27 million, with treasury holdings representing 0.04 percent of authorised capital.